CO2017011220A2 - Proceso para la fabricación de mezclas de polvo seco - Google Patents

Proceso para la fabricación de mezclas de polvo seco

Info

Publication number
CO2017011220A2
CO2017011220A2 CONC2017/0011220A CO2017011220A CO2017011220A2 CO 2017011220 A2 CO2017011220 A2 CO 2017011220A2 CO 2017011220 A CO2017011220 A CO 2017011220A CO 2017011220 A2 CO2017011220 A2 CO 2017011220A2
Authority
CO
Colombia
Prior art keywords
dry powder
relates
mixing
manufacture
powder mixtures
Prior art date
Application number
CONC2017/0011220A
Other languages
English (en)
Inventor
Abhishek Gupta
Herbert Clark Chiou
Samiran De
Franciscus Koppenhagen
Xian-Ming Zeng
Original Assignee
Lupin Atlantis Holdings Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings Sa filed Critical Lupin Atlantis Holdings Sa
Publication of CO2017011220A2 publication Critical patent/CO2017011220A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN La invención se refiere a procesos para mezclado de polvo seco. Específicamente, la invención se refiere a mezclado de polvo seco de materia sólida no farmacéutica de partículas y polvos. Más específicamente, la invención se refiere a mezclado de polvo seco de micropartículas, y a mezclas de polvo seco para su uso como productos farmacéuticos. En particular, la presente invención se refiere a un proceso de preparación de una mezcla de polvo seco de micropartículas que comprende uno o más ingredientes farmacéuticos activos (API) y opcionalmente uno o más portadores no micronizados farmacéuticamente aceptables y/o excipientes, en donde el proceso comprende los pasos de ‘mezclar por pulsos’ los ingredientes farmacéuticos activos micronizados y los portadores farmacéuticamente aceptables y/o excipientes.
CONC2017/0011220A 2015-04-01 2017-10-31 Proceso para la fabricación de mezclas de polvo seco CO2017011220A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN380KO2015 2015-04-01
PCT/IB2016/000418 WO2016156970A1 (en) 2015-04-01 2016-04-01 Process for manufacturing dry powder blends

Publications (1)

Publication Number Publication Date
CO2017011220A2 true CO2017011220A2 (es) 2018-01-16

Family

ID=56024334

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011220A CO2017011220A2 (es) 2015-04-01 2017-10-31 Proceso para la fabricación de mezclas de polvo seco

Country Status (14)

Country Link
US (1) US10617646B2 (es)
EP (1) EP3277265A1 (es)
CN (1) CN107864622A (es)
AU (1) AU2016241369A1 (es)
BR (1) BR112017021111A2 (es)
CA (1) CA2981440A1 (es)
CL (1) CL2017002470A1 (es)
CO (1) CO2017011220A2 (es)
EA (1) EA201792159A1 (es)
IL (1) IL254814A0 (es)
MA (1) MA41855A (es)
MD (1) MD20170094A2 (es)
MX (1) MX2017012633A (es)
WO (1) WO2016156970A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
KR20100095437A (ko) * 2007-11-07 2010-08-30 아스트라제네카 아베 아스코르브산 유도체를 포함하는 건조 분말 제제
WO2013091006A1 (en) * 2011-12-23 2013-06-27 Monash University Process for dry powder blending
GB201205632D0 (en) * 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
WO2015034678A2 (en) * 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

Also Published As

Publication number Publication date
IL254814A0 (en) 2017-12-31
BR112017021111A2 (pt) 2018-07-03
CA2981440A1 (en) 2016-10-06
CN107864622A (zh) 2018-03-30
EP3277265A1 (en) 2018-02-07
EA201792159A1 (ru) 2018-01-31
US10617646B2 (en) 2020-04-14
AU2016241369A1 (en) 2017-11-02
MD20170094A2 (ro) 2018-04-30
CL2017002470A1 (es) 2018-04-13
MA41855A (fr) 2021-03-31
US20180071218A1 (en) 2018-03-15
MX2017012633A (es) 2018-06-20
WO2016156970A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
PH12018502516A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
NZ631100A (en) Soft chewable pharmaceutical products
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
AR102926A1 (es) Composiciones anticancerosas
EA201792345A1 (ru) Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
PE20180522A1 (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
CO2018005920A2 (es) Composiciones y métodos para fabricar micropartículas de proteína
WO2014118808A3 (en) Ticagrelor solid dispersion
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
GEP20207157B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
EA201592172A1 (ru) Проглатываемые таблетки n-ацетилцистеина
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
CO2017011220A2 (es) Proceso para la fabricación de mezclas de polvo seco
WO2015119924A3 (en) Fixed-dose combinations of antiviral compounds
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
TN2016000484A1 (en) Ceritinib formulation.